Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer

OBJECTIVE: Patients with BRAF-mutant colorectal cancer (CRC) have a poor prognosis. Molecular status is not currently used to select which drug to use in combination with radiotherapy. Our aim was to identify drugs that radiosensitise CRC cells with known BRAF status. METHODS: We screened 298 oncolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Rebecca, Cheraghchi-Bashi, Azadeh, Westhorpe, Adam, Yu, Sheng, Shanneik, Yasmin, Seraia, Elena, Ouaret, Djamila, Inoue, Yasuhiro, Koch, Catherine, Wilding, Jenny, Ebner, Daniel, Ryan, Anderson J., Buffa, Francesca M., Sharma, Ricky A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713640/
https://www.ncbi.nlm.nih.gov/pubmed/31516745
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713640/
https://www.ncbi.nlm.nih.gov/pubmed/31516745
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0284

Ejemplares similares